Researchers from the Schepens Eye Research Institute of Massachusetts Eye and Ear have successfully prevented mice from developing angiogenesis of the retina using gene-editing techniques with CRISPR-Cas9.
According to researchers, since it is known vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) plays an essential role in angiogenesis, the CRISPR-Cas9 system can be used to edit the VEGFR2 gene, helping prevent intraocular pathological angiogenesis. This, says researchers, could be used to treat patients who do not respond to anti-VEGF therapies.
The study was recently published in the journal Nature Communications.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: Massachusetts Eye and Ear